Authors of a newly published study on the use of an antidepressant for COVID-19 claim the drug greatly reduces hospitalizations and mortality. But some experts question whether that’s really what the data show.

Long-term administration of the antidepressant fluoxetine was tied to decreased concentrations of about 100 different brain lipids in adolescent macaques, hinting at a potential mechanism underlying the drug’s rare but severe side effects.

The effects of the therapy in a small group of  patients were long-lasting, researchers say, adding to evidence that the approach works for treatment-resistant depression.

It could be a throwback to a mechanism that induces ovulation during sex, researchers propose, but not everyone thinks the results can be extrapolated to people.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

Some researchers and animal rights groups are amplifying their opposition to an assay that measures how long a rodent tries to stay afloat.

The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.

The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.

Fluoxetine dampened stress responses in zebrafish embryos exposed to the drug—and their descendants.

The compound, BCI-838, is already in human clinical trials as a possible treatment for depression.

Impairments in the production of neurotransmitters may lead to depression in some patients, preliminary results show, opening new avenues for research.

Beyond Biocentrism, The Sting of the Wild, The Birth of Anthropocene, and Ordinarily Well

Structural studies reveal how SSRI drugs bind to the human serotonin transporter.

An SSRI commonly prescribed to treat depression could help prevent the formation of Alzheimer’s disease-associated amyloid plaques.

Researchers show that lanicemine is an effective antidepressant without the adverse effects of the related hallucinogenic drug.

A newly recognized chemical factor in the brain, called neuritin, regulates plasticity and may play a role in depression.

What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.